A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors

Conclusions Crenigacestat was tolerated in Japanese patients but with limited clinical activity. The recommended crenigacestat dose in Japanese patients is 50  mg TIW.Trial registration: NCT02836600 (ClinicalTrials.gov) registered on July 19, 2016.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research